Orchestra BioMed Holdings (OBIO) Other Non Operating Income (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported Other Non Operating Income of -$35000.0 for Q1 2026, down 218.18% on a QoQ basis from -$11000.0 in Q1 2024.
Orchestra BioMed Holdings (OBIO) has 3 years of Other Non Operating Income data on file, last reported at -$35000.0 in Q1 2026.
- Quarterly Other Non Operating Income changed N/A year-over-year to -$35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35000.0 (changed N/A YoY) and the FY2025 annual result came in at $254000.0, up 2409.09% from the prior year.
- Other Non Operating Income eased to -$35000.0 in Q1 2026 per OBIO's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $682000.0 in Q2 2022 and bottomed at -$35000.0 in Q1 2026.
- The 3-year median for Other Non Operating Income is -$11000.0 (2024), against an average of $212000.0.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35,000.00 |
| Mar 31, 2024 | -11,000.00 |
| Jun 30, 2022 | 682,000.00 |